How much are GLP-1 drugs boosting medspa revenue?

Galderma reported a 25% sales lift in aesthetics directly attributable to GLP-1 users. The demand comes from both preventive treatments (Dysport, Radiesse, Sculptra) to address volume loss and skin laxity, and corrective procedures post-weight loss for skin tightening and contour restoration.

What aesthetic procedures are GLP-1 patients requesting?

GLP-1 users are driving demand for preventive injectables like Dysport to combat 'Ozempic face,' volumizing fillers like Radiesse, and biostimulators like Sculptra. Post-weight loss, they're also seeking skin tightening and filler for restored facial contour.

Which markets are seeing the biggest GLP-1 aesthetics boom?

Urban, higher-income markets show the strongest uptick in GLP-1-driven aesthetics demand, correlating directly with higher GLP-1 penetration rates in those regions. Practices in these areas should expect sustained volume increases for preventive and corrective procedures.

How should medspa practices market to GLP-1 patients?

Marketing messaging around 'GLP-1 support' and skin quality maintenance is becoming essential for practices serving these patients. Positioning preventive toxin, volumizing fillers, and biostimulators as solutions for maintaining facial volume and skin elasticity during weight loss is now table stakes.

Will GLP-1 demand for aesthetics continue to grow?

Yes—Galderma's data confirms this is not speculative, and the tailwind is expected to persist as GLP-1 adoption continues to climb. Practices should prepare for sustained case-mix shifts toward preventive and corrective aesthetics in high-penetration markets.

Monday, August 24, 2026 Never miss a recall or a rule change Go Pro · $20/mo →

RegulatoryAbbVie Launches Phase 2 Forehead Lines Studytoday MarketFacial Rejuvenation Market Forecast to Hit $5.66B by 20302 days ago Business & M&AAllergan Aesthetics Overhauls Loyalty Programtoday Devices & TechXERF Technology Enters Australian Market for Skin Tightening2 days ago Business & M&AEvolus Expands Estyme to Canada, Australia, New Zealandtoday MarketArm Fat Now Top Body Sculpting Concern in Singapore2 days ago Devices & TechSofwave Hits One Million Treatments Milestonetoday RegulatoryCKD Bio Pursues China Botox Approval—2027 Launch Targeted2 days ago RegulatoryRevance Wins FDA Nod for Under-Eye Injectablesyesterday MarketGLP-1 Pill Era Is Forcing Beauty Market Shiftyesterday InjectablesAEON Releases Expanded ABP-450 Botox Biosimilar Datayesterday Devices & TechUltherapy PRIME Real-Time Imaging Reshapes Midface Liftingyesterday

Market

GLP-1 Weight Loss Boom Lifts Galderma Aesthetics Sales 25%

CEO confirms GLP-1 users driving preventive and corrective aesthetics demand—practices should prepare for sustained volume and case-mix shifts.

By Evan at Inside MedSpa · Jul 31, 2026

Galderma's CEO confirmed that the surge in GLP-1 weight-loss drug adoption is directly boosting the company's aesthetics sales by approximately 25%, a material contribution to the company's record H1 2026 performance. The driver is twofold: GLP-1 users seeking preventive injectables to mitigate "Ozempic face" (volume loss, skin laxity) and corrective procedures post-weight loss (skin tightening, filler for restored contour).

This is not speculative. Galderma's data shows measurable uptick in Dysport, Radiesse, and Sculptra volume among practices serving GLP-1-using patient cohorts. The effect is strongest in urban, higher-income markets where GLP-1 penetration is highest.

Inside MedSpa Pro

You've reached your free articles this week.

Keep reading every article, unlock the full trackers, and get the twice-a-week intelligence brief — from $20/mo, or $200/yr (two months free). Never miss a recall or a rule change.

Every article, unlocked — no weekly limit
The full 50-state law tracker, stock & M&A watch
The twice-a-week, 2-minute intelligence brief
Recalls, FDA clearances & safety signals as they hit

See everything you get →

Cancel anytime, one click · 14-day money-back on annual

https://insidemedspa.com/article/galderma-glp-1-aesthetics-sales-boost-25-percent/

Discussion

Free alerts

Get flagged before it costs you.

We'll flag the moment a recall or rule change hits your practice. One email a week, one click to leave.

Free · weekly · unsubscribe anytime. Privacy.

This morning's brief · 6 AM

The free version stops here.

What today's moves mean for your margins — and exactly what to do — already went out to Pro. By the time the trade press explains it, the window to act has closed.

Go Pro · $20/mo Two minutes a morning. Cancel anytime.

Live · Market movers

STRATA Skin Sciences-50%Hims & Hers Health+6.03%Estée Lauder+6.02%Bausch Health (Solta)-5.43%The Beauty Health Company (HydraFacial)+3.65%

The full stock & M&A watch →

FDA Activity — Aesthetic Devices

Monthly 510(k) clearances vs. recalls.

510(k) clearances Recalls

FDA Activity — Aesthetic Devices — Monthly 510(k) clearances vs. recalls.
Month	510(k) clearances	Recalls
Jun '25	0	4
Jul '25	0	1
Sep '25	0	1
Oct '25	0	2
Jan '26	0	1
Feb '26	0	5
Mar '26	0	5
Apr '26	0	19
May '26	7	18
Jun '26	34	8
Jul '26	23	4
Aug '26	5	0

The 50-state regulation tracker →

Inside MedSpa Pro

By the time it's news, it's too late.

The rebate cut, the scope-of-practice bill, the competitor opening down the street — it hits your business before the trade press ever covers it. Pro gets you there first: what happened, why it touches your margins, and exactly what to do — at 6 AM, in two minutes.

Go Pro · $20/mo Never miss a recall or a rule change. Cancel anytime.

The twice-a-week intelligence brief Go Pro · $20/mo →

GLP-1 Weight Loss Boom Lifts Galderma Aesthetics Sales 25%

Share

Discussion

Leave a comment

By the time it's news, it's too late.